Vascular Smooth Muscle Cells Are the Key to Functional Engineered Blood Vessels

Cardiovascular diseases remain the leading cause of death worldwide, driving a persistent demand for vascular grafts. While autologous vessels like the saphenous vein are the gold standard for bypass surgery, many patients lack suitable donor tissue due to prior harvest, disease, or anatomical limitations. Synthetic grafts made from Dacron or ePTFE work well for large-diameter arteries but fail in small-diameter applications (less than 6 mm) because of thrombosis and intimal hyperplasia. Tissue-engineered blood vessels (TEBVs) offer a compelling alternative, combining biodegradable scaffolds with living cells to create constructs that can grow, remodel, and integrate with the host. Among the cellular components of an engineered vessel, vascular smooth muscle cells (VSMCs) stand out as the primary determinants of mechanical strength, contractile function, and long-term patency. Understanding the multifaceted biology of VSMCs and translating that knowledge into robust engineering strategies is essential for moving TEBVs from the lab bench to the operating room.

What Are Vascular Smooth Muscle Cells? A Deep Dive

VSMCs are highly specialized, non-striated muscle cells that reside in the tunica media of arteries and veins. In native vessels, they exist in a quiescent, contractile phenotype characterized by abundant contractile proteins such as α-smooth muscle actin (α-SMA), smooth muscle myosin heavy chain (SM-MHC), and calponin. These cells respond to hemodynamic forces and neurohumoral signals, contracting and relaxing to regulate vessel diameter, blood pressure, and regional blood flow. However, VSMCs are not terminally differentiated; they retain remarkable phenotypic plasticity. In response to injury, growth factors, or changes in the extracellular matrix (ECM), they can switch to a synthetic or proliferative phenotype, downregulating contractile markers and upregulating ECM production, matrix metalloproteinases, and promigratory proteins. This plasticity is essential for vessel development, repair, and remodeling, but it also poses a major challenge in tissue engineering: maintaining the desired phenotype within an engineered construct over time.

Beyond contractility and ECM synthesis, VSMCs also serve a critical barrier function. They help regulate the passage of macromolecules and cells through the vessel wall, contribute to the production of elastic fibers that provide recoil, and interact with endothelial cells through paracrine signaling to maintain vascular homeostasis. In small-diameter TEBVs, a functional VSMC layer is often the difference between a graft that stays open and one that fails due to thrombosis or aneurysm.

The Critical Role of VSMCs in Engineered Blood Vessels

In a tissue-engineered blood vessel, VSMCs are not merely filler cells. They are the architects of the vessel wall’s mechanical and biological properties. Their roles can be broken down into several interrelated functions.

Contractility and Vasoreactivity

A major advantage of living TEBVs over synthetic grafts is their ability to actively regulate blood flow. When properly differentiated, VSMCs in the engineered wall can contract in response to agonists such as endothelin-1, angiotensin II, and potassium chloride, and relax in response to nitric oxide or prostacyclin. This vasoreactivity helps match perfusion to tissue demand and dampens pulse pressure, reducing the risk of downstream organ damage. Researchers often measure the contractile force of engineered vessels in bioreactors by perfusing with vasoactive agents and tracking diameter changes. Achieving a contractile response comparable to native arteries remains a benchmark for TEBV maturation.

Structural Support and ECM Production

The mechanical strength of a blood vessel comes primarily from the ECM secreted by VSMCs. Collagen type I and III provide tensile strength, while elastin gives the vessel its elastic recoil. In engineered constructs, VSMCs are seeded onto a scaffold—often a biodegradable polymer like polycaprolactone (PCL), polyglycolic acid (PGA), or a decellularized matrix—and then cultured under dynamic conditions. Over weeks to months, the VSMCs degrade the scaffold and replace it with their own ECM. The resulting construct can develop burst pressures exceeding 2000 mmHg and compliance approaching that of native arteries. Without a robust VSMC population, the vessel wall remains thin and prone to aneurysm or rupture.

Healing, Integration, and Remodeling

Upon implantation, a TEBV is subjected to injury and inflammation. Host-derived immune cells infiltrate the wall, and circulating progenitor cells may engraft. VSMCs in the construct can proliferate and migrate to repopulate areas of cell loss, and they produce matrix to repair microtears. Over time, the engineered vessel remodels to resemble a native artery, with VSMCs aligning circumferentially and expressing mature contractile markers. This remodeling process is essential for long-term patency and is one of the most compelling arguments for using living cells rather than an acellular scaffold.

Inhibition of Thrombosis and Intimal Hyperplasia

A functional VSMC layer also contributes to the antithrombotic properties of the vessel wall. Contractile VSMCs produce thrombomodulin and tissue factor pathway inhibitor, and they maintain a non-thrombogenic surface when the endothelial layer is intact. In cases where the endothelium is damaged or absent—common at anastomotic sites—the underlying VSMCs can help limit platelet activation and thrombus formation. Additionally, VSMCs that remain in a quiescent phenotype are less likely to contribute to neointimal hyperplasia, the abnormal smooth muscle cell proliferation that leads to graft failure. Engineering strategies that promote a stable contractile VSMC phenotype are therefore key to preventing both thrombosis and hyperplasia.

Sources of VSMCs for Tissue Engineering

The choice of VSMC source dramatically affects the performance of the final construct. Each source has advantages and limitations that must be weighed against the clinical target.

Primary Arterial VSMCs

The most straightforward source is primary VSMCs isolated from donor arteries (e.g., from internal thoracic artery remnants or a patient’s own saphenous vein). These cells are already committed to the smooth muscle lineage and can be expanded in culture. However, they have a finite replicative lifespan and may undergo phenotypic drift toward the synthetic state during expansion. For autologous use, harvest of a donor vessel is invasive and may be impractical in patients with vascular disease. Allogeneic sources risk immune rejection unless the recipient is immunosuppressed or the cells are engineered to evade the immune system.

Stem Cell-Derived VSMCs

Stem cells provide a scalable and potentially autologous source of VSMCs. Pluripotent stem cells (iPSCs or ESCs) can be directed toward a smooth muscle fate using protocols involving growth factors like PDGF-BB, TGF-β1, and activin A. The resulting VSMC-like cells express contractile markers and can contract in vitro. Mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or umbilical cord also differentiate into smooth muscle-like cells under appropriate conditions and have the advantage of immunomodulatory properties. However, the differentiation efficiency and phenotype stability of stem cell-derived VSMCs remain areas of active investigation. Off-target differentiation and tumorigenicity (in the case of iPSCs) must be carefully controlled.

Induced VSMCs via Direct Reprogramming

An emerging approach is direct conversion of fibroblasts or other somatic cells into VSMCs using lineage-specific transcription factors such as MYOCD (myocardin) and SRF. This method avoids the pluripotent stage and may yield a more homogeneous population. Early studies show that reprogrammed VSMCs can contribute to vessel formation in vivo, but the field is still preclinical.

Scaffold Design and Culture Strategies

To harness the full potential of VSMCs, the scaffold must provide appropriate mechanical support, biochemical cues, and a degradation rate that matches ECM deposition. Three broad categories of scaffolds are used.

Natural Scaffolds

Collagen, fibrin, and hyaluronic acid hydrogels offer excellent biocompatibility and cell adhesion sites. VSMCs embedded in these gels can remodel them, but the initial mechanical strength is low. Fibrin has been used successfully in several TEBV models, including the so-called “self-assembled” vessel sheets, where VSMCs are cultured in a fibrin gel that they gradually replace with ECM. The process takes weeks and requires a bioreactor to apply cyclic stretch, which upregulates elastin and collagen synthesis.

Synthetic Biodegradable Polymers

Polymers such as PCL, PGA, polylactic acid (PLA), and poly(lactic-co-glycolic acid) (PLGA) can be electrospun into nanofibrous meshes that mimic the architecture of native ECM. These scaffolds provide immediate mechanical strength and can be tailored to degrade over weeks to months. VSMCs seeded onto these scaffolds attach, proliferate, and deposit ECM. A key challenge is achieving uniform cell distribution throughout the thickness of the wall, especially in clinically relevant vessel lengths (5–20 cm). Dynamic seeding methods using rotational or perfusion systems improve coverage.

Decellularized Matrices

Decellularized human or animal vessels retain the native ECM architecture and composition, including collagen, elastin, and glycosaminoglycans. After removing cellular antigens, these scaffolds can be recellularized with VSMCs (and endothelial cells) to produce a “hybrid” vessel. The recellularized vessel often shows excellent mechanical properties and vasoreactivity, but the decellularization process may damage ECM components, and complete removal of immunogenic epitopes from xenogeneic sources is difficult.

Mechanical Conditioning in Bioreactors

Regardless of scaffold type, dynamic culture is almost always required to produce a functional TEBV. Bioreactors apply pulsatile flow and cyclic circumferential stretch, which mimic the hemodynamic environment of a native artery. Mechanical forces activate signaling pathways (e.g., RhoA/ROCK, integrin-mediated mechanotransduction) that promote the contractile VSMC phenotype and stimulate ECM alignment and crosslinking. Typical protocols involve low-flow perfusion for the first week to allow cell attachment, followed by increasing flow and pressure over 4–8 weeks. The result is a vessel that can be implanted surgically and remain patent.

Current Challenges in VSMC-Based Engineered Vessels

Despite significant progress, several hurdles prevent widespread clinical use of TEBVs.

Phenotype Stability

The single greatest challenge is maintaining a contractile VSMC phenotype from the time of seeding through the implant’s life. In static culture, VSMCs rapidly switch to a synthetic state and produce excessive matrix that can occlude the lumen (neointimal hyperplasia). Once implanted, the vessel is exposed to a complex, inflammatory milieu that can further drive phenotype switching. Strategies to stabilize the contractile phenotype include the use of chemically defined media (low serum, addition of heparin or TGF-β), mechanical preconditioning, and co-culture with endothelial cells, which release nitric oxide that helps keep VSMCs quiescent.

Immune Response

Allogeneic or xenogeneic VSMCs will trigger an immune response unless the host is immunosuppressed. Even autologous VSMCs may provoke inflammation if they are modified (e.g., by gene editing) or if the scaffold material is immunogenic. Decellularized scaffolds avoid cell-associated antigens but lack the living VSMC component. Some groups are exploring “universal donor” VSMCs engineered to express immune-evasive molecules such as HLA-E or PD-L1, but this work is in early stages.

Nutrient Diffusion and Cell Survival

In thick-walled vessels (greater than 200–300 μm), oxygen and nutrients cannot reach the interior VSMCs by diffusion alone. Without a functional microvasculature, cells in the center of the wall can die during culture or after implantation. Strategies to overcome this include co-culturing with endothelial cells that form capillary-like networks, using oxygen-generating scaffolds, or creating a porous scaffold that allows rapid vascularization from the host. Some groups are investigating small-diameter vessel grafts with pre-formed channels that promote host vessel ingrowth.

Scalability and Manufacturing

Producing a TEBV that meets regulatory standards requires a reproducible, cost-effective manufacturing process. Current methods often involve weeks of cell expansion and bioreactor culture, with manual steps that are labor-intensive and prone to variability. The development of closed-system bioreactors, automated cell seeding, and quality control assays (e.g., for contractile marker expression, burst pressure) will be essential for translating TEBVs to commercial production.

Future Directions and Innovations

Several emerging technologies promise to address the challenges described above.

Gene Editing for Phenotype Control

CRISPR-based tools can be used to engineer VSMCs that are resistant to phenotypic switching or that overexpress contractile proteins. For example, knocking in a constitutively active myocardin transgene or deleting KLF4 (a transcription factor that drives the synthetic phenotype) could lock VSMCs in a contractile state. Similarly, gene editing can produce cells that evade immune recognition or that express pro-angiogenic factors to promote host integration.

3D Bioprinting

Bioprinting allows precise spatial control over cell distribution, scaffold composition, and even the orientation of printed fibers. Multi-axis inkjet or extrusion printers can deposit layers of VSMC-laden hydrogels, polymer shells, and endothelial cells to build a vessel with defined geometry. Several groups have printed small-caliber arteries with open lumens and have demonstrated contractile responses after culture. The challenge is achieving the mechanical strength needed for implantation, but co-printing with biodegradable polymers may provide a solution.

Organoids and Self-Assembled Vessels

An alternative to scaffold-based approaches is to allow VSMCs to self-organize into a vessel structure. By culturing VSMCs on a tubular mandrel in a defined medium, some groups have produced acellular vessels that are robust enough for implantation after decellularization. Others have created “smooth muscle organoids” that exhibit spontaneous contractile activity and can be used to study vascular diseases or test drug responses.

Clinical Translation and Ongoing Trials

Several TEBV platforms have entered clinical testing. The most advanced is the “Lifeline” graft (CytoGraft, now part of Humacyte), which uses allogeneic VSMCs seeded onto a biodegradable scaffold in a bioreactor, then decellularized before implantation. This acellular graft contains a rich ECM produced by VSMCs but avoids live cell immunogenicity. Early clinical trials in hemodialysis access and peripheral arterial disease have shown promise, with patency rates approaching those of autologous vein grafts in some studies. Other groups are exploring fully living grafts with autologous cells, though these require more patient-specific manufacturing.

For further reading, see this review of VSMC phenotype regulation and this Nature Reviews Cardiology overview of tissue-engineered vascular grafts. Additional details on scaffold materials can be found in this Biomaterials article.

Conclusion

Vascular smooth muscle cells are far more than a structural filler in engineered blood vessels. They provide the contractile function that makes a graft responsive to hemodynamic demands, build and maintain the extracellular matrix that gives the vessel its mechanical integrity, and participate in healing and remodeling after implantation. The successful translation of TEBVs to the clinic depends on our ability to source VSMCs reliably, maintain their desired phenotype throughout culture and post-implantation, and design scaffolds that support their function. With advances in stem cell biology, gene editing, bioreactor design, and 3D bioprinting, the goal of producing off-the-shelf, durable, small-diameter vascular grafts is moving closer to reality. As the field continues to mature, the role of VSMCs will remain central to every breakthrough.